653. Myeloma: Therapy, excluding Transplantation I

Meletios A. Dimopoulos1, Darrell J. White, MD2, Lofti Benboubker, MD3*, Gordon Cook, et al.

The authors conclude that:

This updated analysis reveals that DRd continues to demonstrate a significant PFS benefit compared with Rd alone, and pt responses continue to deepen with DRd with longer follow up. Pts who receive DRd demonstrated longer time to next therapy and responded more favorably to subsequent therapy as evidenced by prolonged PFS2, suggesting that patients continue to observe clinical benefit from prior daratumumab treatment. Importantly, the favorable safety profile was maintained with longer follow-up. These data support the addition of daratumumab to standard of care regimens in RRMM.


Jesus G. Berdeja, MD1, Yi Lin, MD, PhD2, Noopur Raje, MD3, Nikhil Munshi, et al. and James N. Kochenderfer, MD10

The authors conclude that:

bb2121 shows promising efficacy at dose levels above 50 x 106 CAR+ T cells, with manageable CRS and no DLTs to date. ORR was 100% at these dose levels with 8 ongoing clinical responses at 6 months and 1 patient demonstrating a sustained response beyond one year. These initial data support the potential of CAR T therapy with bb2121 as a new treatment paradigm in RRMM.

Suzanne Trudel, MD, FRCP(C)1, Nikoletta Lendvai, MD, PhD2, Rakesh Popat3*, Peter M. Voorhees, et al.

The authors conclude that:

GSK2857916 monotherapy demonstrated encouraging single agent activity with an ORR of 60%, and deep (51% ≥VGPR) and durable responses in heavily pre-treated relapsed/refractory MM pts who have limited treatment options. The target and therapeutic mechanisms of action differentiate GSK2857916 from currently approved drugs in MM. Results show a manageable safety profile, with thrombocytopenia/platelet count decreased and low grade corneal events being the most frequently reported AEs and most frequent reason for dose modifications. Detailed safety and clinical activity together with results from correlative analyses will be presented.

Eric L Smith, MD, PhD1, Sham Mailankody, MBBS2*, Arnab Ghosh, MBBS, PhD3*, Reed Masakayan, et al.

The authors found that:

Objective responses by IMWG criteria after a single dose of CAR T cells were observed across both DLs. At DL1, of 3 pts, responses were 1 VGPR, 1 SD, and 1 pt treated with baseline Mspike 0.46, thus not evaluable by IMWG criteria, had >50% reduction in Mspike, and normalization of K/L ratio. At DL2, 2/2 pts had objective responses with 1 PR and 1 VGPR (baseline 95% marrow involvement); 1 pt is too early to evaluate. As we are employing a human CAR, the study was designed to allow for an optional second dose in pts that do not reach CR. We have treated 2 pts with a second dose, and longer follow up data is pending.

A. Keith Stewart, MBChB, MBA1, David Siegel, MD, PhD2, Heinz Ludwig, MD3, Thierry Facon, MD4*, et al.

The authors conclude that:

KRd demonstrated a statistically significant and clinically meaningful 21% reduction in the risk of death vs Rd. KRd should be considered a standard of care in RRMM.

Alessandra Larocca1*, Massimo Offidani, MD2, Pellegrino Musto, MD2, Francesca Patriarca, et al.

The authors conclude that:

BORT treatment resulted in a PFS and OS benefit vs LEN in patients with HiR cytogenetics. Treatment with VMP led to a significant reduction of the risk of death or progression vs Rd in HiR patients. These results support VMP induction as a standard treatment option for patients with NDMM who are ineligible for transplant with HiR cytogenetics.